ALIGOS THERAPEUTICS INC (ALGS) Stock Analyst Ratings
NASDAQ:ALGS - Nasdaq - US01626L2043 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 84% to ALGS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 103.7. This target is 1611.22% above the current price.
ALGS was analyzed by 9 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about ALGS.
In the previous month the buy percentage consensus was at a similar level.
ALGS was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-03-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-19 | HC Wainwright & Co. | Initiate | Buy |
| 2023-01-17 | Piper Sandler | Maintains | Overweight |
| 2023-01-06 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2023-01-06 | Jefferies | Upgrade | Hold -> Buy |
| 2022-11-03 | SVB Leerink | Maintains | Market Perform |
| 2022-05-05 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022-03-11 | SVB Leerink | Maintains | Outperform |
| 2022-03-11 | Piper Sandler | Maintains | Overweight |
| 2022-02-16 | SVB Leerink | Maintains | Outperform |
| 2022-01-07 | SVB Leerink | Maintains | Outperform |
| 2022-01-07 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2021-09-09 | SVB Leerink | Initiate | Outperform |